ELECTRONIC DISPLAY SCREEN

I. Market Insight: The New Standard of EfficacyOn February 23, 2026, Novo Nordisk released the REDEFINE 4 Phase 3 results—a head-to-head trial to challenge Eli Lilly’s GLP-1 market dominance. Data ...

       Recently, a major collaboration between Pfizer and Xianweida has become a hot topic in the global pharmaceutical industry — the two parties have joined hands to promote the commercializatio...

Ⅰ. A historic shiftIn 2025, the global pharmaceutical industrysaw a historic shift: Eli Lilly’s tirzepatide narrowlydethroned Novo Nordisk’s semaglutide as the new"King of Pharmaceuticals" with $36...

1. Hot Spot Cut-In: Eli Lilly’s Trial Boosts GLP-1 Peptide API DemandOn January 8, 2026, Eli Lilly and Company announced positive top-line results from its Phase IIIb TOGETHER-PsA study, evaluating...

Seattle, USA — A pivotal shift from café menus to core manufacturing is underway, as global coffee giant Starbucks takes the lead in adapting to GLP-1-driven dietary changes by launching and expan...

Utide Honored with National Peptide Industry Award for Scalable ProductionThe 11th National Conference on Peptide Drug R&D and Large-Scale Production Frontier Technology successfully convened in Sa...

Breaking News: Guizhou Utide Biotechnology’s Tirzepatide and Retatrutide Successfully Pass U.S. Drug Master File (DMF) Filing for Peptide Active Pharmaceutical Ingredients!Recently, the U.S. Food a...

中国多肽化妆品市场进入高速增长期中国多肽化妆品市场虽起步较晚，但凭借独特的市场活力和快速迭代的本土创新，已成为全球美妆行业增长最快的细分领域之一。尽管国际品牌在肽类成分研发上拥有先发优势，但受限于市场战略错位和本土化不足，其技术积累并未转化为市场主导力。相反，以韩束为代表的国产品牌通过精准定位和技术突破，成功占据消费者心智，推动市场呈现“国货主导、多极竞争”的格局。截至2025年，该市场仍处...